Clinical Trials

Study closed to enrollment

Inclusion Criteria:

• Diagnosis of metastatic Stage IV NSCLC
• At least 1 measurable extra-central nervous system (CNS) lesion
• Documented radiographic progression while on continuous treatment with erlotinib monotherapy
• Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease ≥ 6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease
• Determined to be MET diagnostic positive (+)
• Availability of a tumor sample post-erlotinib progression
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Have adequate organ function

Exclusion Criteria:

• Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device
• Have previously been treated with LY2875358 or any other MET-targeting experimental therapeutic
• Have a serious concomitant systemic disorder or significant cardiac disease
• Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently
• Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study
• Have major surgery less than 2 weeks prior initiation of study treatment therapy
• Pregnant or lactating women
• Have symptomatic CNS metastasis